SLC6A3 and Parkinson disease: Furthermore, PTX, by increasing the levels of DA, TH, and DAT and decreasing TNF-alpha, appears as a potential candidate to be included in clinical trials, alone or associated with other anti-inflammatory drugs, for the treatment of neurodegenerative pathologies as Parkinson's disease.